Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clare Jolly

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Nature Microbiology|January 16, 2024
Evolution of enhanced innate immune suppression by SARS-CoV-2 Omicron subvariantsAnn-Kathrin Reuschl, Lucy G Thorne, Matthew V X Whelan, et al.
Cell Reports|August 14, 2025
Signatures of omicron-like adaptation in early SARS-CoV-2 variants and chronic infectionMark Tsz Kin Cheng, Mazharul Altaf, Jesu Castin, et al.
Nature Communications|February 10, 2025
Macrocycle-based PROTACs selectively degrade cyclophilin A and inhibit HIV-1 and HCVLydia S Newton, Clara Gathmann, Sophie Ridewood, et al.
Biorxiv : the Preprint Server for Biology|January 27, 2021
Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variantAnn-Kathrin Reuschl, Lucy G Thorne, Lorena Zuliani-Alvarez, et al.
Nature Communications|May 15, 2021
Targeting human Acyl-CoA:cholesterol acyltransferase as a dual viral and T cell metabolic checkpointNathalie M Schmidt, Peter A C Wing, Mariana O Diniz, et al.
EMBO Reports|August 24, 2022
Evolutionary remodelling of N-terminal domain loops fine-tunes SARS-CoV-2 spikeDiego Cantoni, Matthew J Murray, Mphatso D Kalemera, et al.
Biorxiv : the Preprint Server for Biology|June 15, 2021
Evolution of enhanced innate immune evasion by the SARS-CoV-2 B.1.1.7 UK variantLucy G Thorne, Mehdi Bouhaddou, Ann-Kathrin Reuschl, et al.
Nature|December 23, 2021
Evolution of enhanced innate immune evasion by SARS-CoV-2Lucy G Thorne, Mehdi Bouhaddou, Ann-Kathrin Reuschl, et al.
Medrxiv : the Preprint Server for Health Sciences|June 2, 2021
Plitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalizationJosé F Varona, Pedro Landete, Jose A Lopez-Martin, et al.
Life Science Alliance|January 11, 2022
Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19Jose F Varona, Pedro Landete, Jose A Lopez-Martin, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Nature Microbiology|January 16, 2024
Evolution of enhanced innate immune suppression by SARS-CoV-2 Omicron subvariantsAnn-Kathrin Reuschl, Lucy G Thorne, Matthew V X Whelan, et al.
Cell Reports|August 14, 2025
Signatures of omicron-like adaptation in early SARS-CoV-2 variants and chronic infectionMark Tsz Kin Cheng, Mazharul Altaf, Jesu Castin, et al.
Nature Communications|February 10, 2025
Macrocycle-based PROTACs selectively degrade cyclophilin A and inhibit HIV-1 and HCVLydia S Newton, Clara Gathmann, Sophie Ridewood, et al.
Biorxiv : the Preprint Server for Biology|January 27, 2021
Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variantAnn-Kathrin Reuschl, Lucy G Thorne, Lorena Zuliani-Alvarez, et al.
Nature Communications|May 15, 2021
Targeting human Acyl-CoA:cholesterol acyltransferase as a dual viral and T cell metabolic checkpointNathalie M Schmidt, Peter A C Wing, Mariana O Diniz, et al.
EMBO Reports|August 24, 2022
Evolutionary remodelling of N-terminal domain loops fine-tunes SARS-CoV-2 spikeDiego Cantoni, Matthew J Murray, Mphatso D Kalemera, et al.
Biorxiv : the Preprint Server for Biology|June 15, 2021
Evolution of enhanced innate immune evasion by the SARS-CoV-2 B.1.1.7 UK variantLucy G Thorne, Mehdi Bouhaddou, Ann-Kathrin Reuschl, et al.
Nature|December 23, 2021
Evolution of enhanced innate immune evasion by SARS-CoV-2Lucy G Thorne, Mehdi Bouhaddou, Ann-Kathrin Reuschl, et al.
Medrxiv : the Preprint Server for Health Sciences|June 2, 2021
Plitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalizationJosé F Varona, Pedro Landete, Jose A Lopez-Martin, et al.
Life Science Alliance|January 11, 2022
Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19Jose F Varona, Pedro Landete, Jose A Lopez-Martin, et al.
Pageof 6